[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:ntrk1-3":3},{"name":4,"total":5,"recruiting":5,"trials":6},"NTRK1-3",2,[7,15],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07405190","Ivonescimab Alone And With Carboplatin\u002FPemetrexed For NSCLC",[11],"Phase 2","RECRUITING","2026-08-26T02:16:44.178623Z","2026-05-05T02:43:28.115654Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT04094610","A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations",[19],"Phase 1\u002FPhase 2","2026-08-26T02:17:57.997171Z","2026-05-05T02:43:27.807992Z"]